DELIVER
Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved-EF Heart Failure
Patient / Population Intervention / Exposure Comparison Outcome
In 6,263 patients with heart failure and an ejection fraction > 40 %, dapagliflozin reduced worsening heart failure or cardiovascular death compared with placebo.
N
6,263
Design
Double-blind RCT
Endpoint
Worsening HF or CV death
Relevance
2
Result16.4 % vs 19.5 % (HR 0.82); benefit consistent across the EF spectrum.
Solomon SD, et al. N Engl J Med. 2022;387(12):1089-1098. 10.1056/NEJMoa2206286
Discussion & critique
With EMPEROR-Preserved, made SGLT2 inhibitors the first broadly effective HFpEF therapy. Driven by HF events; mortality not significantly reduced.